Patients with hematologic malignancies who received unrelated donor bone marrow transplantation had better psychological well-being, less burdensome chronic graft-versus-host disease (GVHD) symptoms, and were more likely to return to work compared with recipients of peripheral blood transplantation at 5 years post-transplantation, a study published in JAMA Oncology has shown.1
Either bone marrow or peripheral blood from unrelated donors may be used for hematopoietic cell transplantation; however, it is unclear which graft source results in improved patient-reported outcomes.
For the study, investigators collected patient-reported outcomes at enrollment and 0.5, 1, 2, and 5 years after transplantation from 551 patients who received 1 of 2 graft sources. Patients were participants of a multicenter randomized clinical trial.
Results showed that at 5 years after transplantation, average Mental Health Inventory Psychological Well-Being scores (P = .01) and Lee chronic GVDH symptom scores (P = .004) were significantly better for bone marrow recipients.
Recipients of bone marrow transplantation were also more likely to be working full or part-time compared with peripheral blood transplantation recipients (P = .002).
There were no significant differences in survival (P = .84), relapse (P = .47), or treatment-related death (P = 0.44) between the 2 graft types.
RELATED: FDA Orders Partial Clinical Hold on NY-ESO SPEAR T-cell Therapy in Liposarcoma
The findings ultimately suggest that bone marrow transplantation from an unrelated donor should be the standard of care for these types of transplant procedures.
- Lee SJ, Logan B, Westervelt P, et al. Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation. JAMA Oncol. 2016 Aug 11. doi: 10.1001/jamaoncol.2016.2520. [Epub ahead of print]